Abbvie And Meiji Seika Begin Fluvoxamine Phase III Trials For Pediatric Obsessive-Compulsive Disorder
This article was originally published in PharmAsia News
Abbvie and Meiji Seika have begun Phase III trials with SSRI fluvoxamine maleate for the treatment of pediatric obsessive-compulsive disorder.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.